Pipeline
Cantex's pipeline has two product candidates in clinical development for diseases where innovative and more effective treatments are greatly needed. DSTAT (formerly known as CX-01) for the treatment of acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML). Dicopp® for the treatment of metastatic pancreatic cancer, recurrent/refractory multiple myeloma, and recurrent pediatric sarcoma.
16915
page-template,page-template-full_width,page-template-full_width-php,page,page-id-16915,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode_grid_1200,qode-theme-ver-18.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.1,vc_responsive
 

Pipeline

Cantex has two product candidates in clinical development:

Dicopp®:

 

  • Blocks mechanisms critical to initiation and propagation of lung and systemic inflammation associated with COVID-19 infection and other lung diseases
  • Blocks mechanisms essential for cancer cell survival
  • Phase 2 trials in 2021
    • “Long –Haulers”: persistent and disabling myalgic encephalitis/chronic fatigue syndrome-like symptoms of COVID-19 infection after virus has cleared
    • Newly diagnosed COVID-19 infection to accelerate recovery and prevent need for hospitalization
    • Relapsed/refractory myeloma
  • Cantex owns issued and pending intellectual property for Dicopp®
  • Dicopp® is a 505(b)(2)product

DSTAT:

 

  • Licensed to Chimerix in July 2019. Continued participation in development via Joint Development Committee
    • Key deal terms:
      • $30 million upfront
      • 10 million shares of Chimerix common stock
      • Payments for achieving sales milestones and regulatory approvals totaling $587.5 million
      • Tiered double-digit royalties on net sales
  • Completed randomized Phase 2 study in acute myeloid leukemia (AML) suggested DSTAT + “7+3” improves event-free and relapse-free survival as well as overall survival without additive toxicity
  • Phase 3 clinical trial in AML to begin in early 2021
  • Pre-clinical data indicates that DSTAT may reduce inflammation, decrease immune cell infiltration and prevent and treat coagulation disorders associated with acute lung injury
  • Phase 2/3 study of DSTAT in COVID-19 associated acute lung injury is in progress
Cantex pipeline graphic